Similarly, Yin et al. (27) demonstrated that combining ctDNA with protein biomarkers (CEA, SqCC, CYFRA21-1) increased sensitivity to 86.4% for early-stage NSCLC, highlighting the potential of multi-analyte approaches. This evidence concerns the gene CEACAM5 and non-small cell lung carcinoma.